Title  | Date  | Price |
|---|
Bayer
Pipeline, Products ,Performance ,Potential
| Oct 2009 |
£595 |
Boehringer Ingelheim: Pipeline, Products, Performance, Potential
| Sep 2009 |
£595 |
Abbott Laboratories: PharmaVitae Profile
| Sep 2009 |
£3,475 |
Bristol-Myers Squibb Co.: PharmaVitae Profile
| Sep 2009 |
£3,475 |
AstraZeneca plc: PharmaVitae Profile
| Sep 2009 |
£3,475 |
Solvay: Pipeline, Products, Performance, Potential
| Sep 2009 |
£595 |
Roche
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Novartis
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Sanofi-Aventis
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Merck
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Wyeth
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
GlaxoSmithKline
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Pfizer
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Johnson & Johnson
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
AstraZeneca
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Bristol-Myers Squibb
Performance, Capabilities, Goals and Strategies in The Worldwide Pharmaceutical Market
| Sep 2009 |
£1,160 |
Merck & Co and Schering-Plough - a marriage of convenience?
| Aug 2009 |
£295 |
Abbott Laboratories: Pipeline, Products, Performance, Potential
| Aug 2009 |
£595 |
BMS & Medarex: a valuable partnership?
| Aug 2009 |
£175 |
Roche & Genentech: a model for future biotech deals?
| Aug 2009 |
£175 |
Johnson & Johnson: Pharma Growth Strategy
How does the world's 7th largest pharma company plan to grow its pharmaceutical revenues?
| Jul 2009 |
£245 |
Eli Lilly & Co.: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Pfizer Inc.: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Novartis AG: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Bayer Schering Pharma AG: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Amgen Inc.: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Pfizer
Pipeline - Products - Performance - Potential
| Jul 2009 |
£595 |
Johnson & Johnson: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Merck & Co. Inc: PharmaVitae Profile
| Jul 2009 |
£3,475 |
Roche
Pipeline - Products - Performance - Potential
| Jun 2009 |
£595 |
Merck KGaA
Pipeline - Products - Performance - Potential
| Jun 2009 |
£595 |
AstraZeneca IMS Company Profile
| Apr 2009 |
£510 |
Genentech IMS Company Profile
| Apr 2009 |
£510 |
Abbott Laboratories-IT Sales Opportunities-2009
| Apr 2009 |
£305 |
Schering-Plough IMS Company Profile
| Apr 2009 |
£510 |
sanofi-aventis IMS Company Profile
| Apr 2009 |
£510 |
Bayer IMS Company Profile
| Apr 2009 |
£510 |
Teva IMS Company Profile
| Apr 2009 |
£510 |
Roche IMS Company Profile
| Apr 2009 |
£510 |
Abbott Laboratories - SWOT Framework Analysis
| Apr 2009 |
£145 |
Allergan - SWOT Framework Analysis
| Apr 2009 |
£145 |
Pfizer - SWOT Framework Analysis
| Apr 2009 |
£145 |
Johnson And Johnson - SWOT Framework Analysis
| Apr 2009 |
£145 |
Novartis IMS Company Profile
| Mar 2009 |
£510 |
Takeda IMS Company Profile
| Mar 2009 |
£510 |
Merck & Co IMS Company Profile
| Mar 2009 |
£510 |
Amgen Inc.: PharmaVitae Profile
Healthcare
| Mar 2009 |
£3,475 |
Bristol-Myers Squibb IMS Company Profile
| Feb 2009 |
£510 |
Astellas Pharma Inc.: PharmaVitae Profile
| Feb 2009 |
£3,475 |
Daiichi Sankyo Co., Ltd: PharmaVitae Profile
| Feb 2009 |
£3,475 |
Wyeth IMS Company Profile
| Feb 2009 |
£510 |
Amgen IMS Company Profile
| Feb 2009 |
£510 |
Abbott IMS Company Profile
| Feb 2009 |
£510 |
Eisai Co. Ltd: PharmaVitae Profile
| Feb 2009 |
£3,475 |
Johnson & Johnson IMS Company Profile
| Feb 2009 |
£510 |
Pfizer IMS Company Profile
| Feb 2009 |
£510 |
Merck KGaA: PharmaVitae Model
| Jan 2009 |
£3,475 |
Forest Laboratories Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Les Laboratoires Servier: PharmaVitae Model
| Jan 2009 |
£3,475 |
Merck & Co. Inc: PharmaVitae Model
| Jan 2009 |
£3,475 |
King Pharmaceuticals Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Genzyme Corporation: PharmaVitae Model
| Jan 2009 |
£3,475 |
Watson Pharmaceuticals Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Teva Pharmaceutical Industries Ltd: PharmaVitae Model
| Jan 2009 |
£3,475 |
Sanofi-Aventis: PharmaVitae Model
| Jan 2009 |
£3,475 |
Shire plc: PharmaVitae Model
| Jan 2009 |
£3,475 |
Amgen Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Allergan Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Wyeth: PharmaVitae Model
| Jan 2009 |
£3,475 |
Eli Lilly & Co.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Pfizer Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Genentech Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Mitsubishi Tanabe (Pharma) IMS Company Profile
| Jan 2009 |
£510 |
Biogen Idec Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Novartis AG: PharmaVitae Model
| Jan 2009 |
£3,475 |
Novo Nordisk A/S: PharmaVitae Model
| Jan 2009 |
£3,475 |
Forest IMS Company Profile
| Jan 2009 |
£510 |
Gilead Sciences Inc.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Boehringer Ingelhgeim GmbH: PharmaVitae Model
| Jan 2009 |
£3,475 |
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Model
| Jan 2009 |
£3,475 |
Solvay S.A.: PharmaVitae Model
| Jan 2009 |
£3,475 |
Shionogi & Co. Ltd: PharmaVitae Model
| Jan 2009 |
£3,475 |
Takeda Pharmaceutical Co. Ltd: PharmaVitae Model
| Jan 2009 |
£3,475 |
Shionogi IMS Company Profile
| Jan 2009 |
£510 |
Schering-Plough Corporation: PharmaVitae Model
| Jan 2009 |
£3,475 |
TAI IMS Company Profile
| Jan 2009 |
£510 |
Daiichi Sankyo Co., Ltd: PharmaVitae Model
| Jan 2009 |
£3,475 |
Genzyme IMS Company Profile
| Dec 2008 |
£510 |
Ono IMS Company Profile
| Dec 2008 |
£510 |
Novo Nordisk IMS Company Profile
| Dec 2008 |
£510 |
Johnson IMS Company Profile
| Dec 2008 |
£510 |
Understanding the Global Pharmaceutical Market
| Nov 2008 |
£300 |
Lundbeck IMS Company Profile
| Nov 2008 |
£510 |
Pfizer Inc.
| Nov 2008 |
£305 |
Watson IMS Company Profile
| Nov 2008 |
£510 |
Forest Laboratories Inc.: PharmaVitae Profile
| Nov 2008 |
£3,475 |
Boehringer Ingelheim IMS Company Profile
| Nov 2008 |
£510 |
UCB: Performance, Products, Pipeline and Potential
| Nov 2008 |
£595 |
Biogen Idec IMS Company Profile
| Oct 2008 |
£510 |
King Pharmaceuticals IMS Company Profile
| Oct 2008 |
£510 |
previous
